|
US7646707B2
(en)
*
|
2003-12-23 |
2010-01-12 |
At&T Intellectual Property I, L.P. |
Method and system for automatically renaming logical circuit identifiers for rerouted logical circuits in a data network
|
|
CN1933847A
(zh)
*
|
2004-01-16 |
2007-03-21 |
密歇根大学董事会 |
Smac肽模拟物及其应用
|
|
BRPI0506883A
(pt)
*
|
2004-01-16 |
2007-05-29 |
Univ Michigan |
miméticos de smac conformacionalmente comprimidos e seus usos
|
|
PL2253614T3
(pl)
|
2004-04-07 |
2013-03-29 |
Novartis Ag |
Inhibitory IAP
|
|
KR100926203B1
(ko)
|
2004-07-02 |
2009-11-09 |
제넨테크, 인크. |
Ｉａｐ의 억제제
|
|
WO2006010118A2
(en)
*
|
2004-07-09 |
2006-01-26 |
The Regents Of The University Of Michigan |
Conformationally constrained smac mimetics and the uses thereof
|
|
BRPI0513310A
(pt)
*
|
2004-07-12 |
2008-05-06 |
Idun Pharmaceuticals Inc |
análogos de tetrapeptìdeo
|
|
JP5230865B2
(ja)
*
|
2004-07-15 |
2013-07-10 |
テトラロジック ファーマシューティカルズ コーポレーション |
Ｉａｐ結合性化合物
|
|
MX2007007195A
(es)
|
2004-12-20 |
2007-10-08 |
Genentech Inc |
Inhibidores de pirrolidina de iap.
|
|
EA012810B1
(ru)
|
2005-02-25 |
2009-12-30 |
Тетралоджик Фармасеутикалс |
Димерные ингибиторы ингибиторов белков апоптоза (iap)
|
|
WO2006122408A1
(en)
|
2005-05-18 |
2006-11-23 |
Aegera Therapeutics Inc. |
Bir domain binding compounds
|
|
CA2617642A1
(en)
*
|
2005-08-09 |
2007-02-22 |
Tetralogic Pharmaceuticals Corporation |
Treatment of proliferative disorders
|
|
US20100256046A1
(en)
*
|
2009-04-03 |
2010-10-07 |
Tetralogic Pharmaceuticals Corporation |
Treatment of proliferative disorders
|
|
AU2006308453B9
(en)
*
|
2005-10-25 |
2011-12-01 |
Pharmascience Inc. |
IAP BIR domain binding compounds
|
|
WO2007106192A2
(en)
*
|
2005-12-19 |
2007-09-20 |
Genentech, Inc. |
Inhibitors of iap
|
|
TWI504597B
(zh)
*
|
2006-03-16 |
2015-10-21 |
Pharmascience Inc |
結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
|
|
BRPI0711591A2
(pt)
|
2006-05-16 |
2011-11-16 |
Aegera Therapeutics, Inc. |
composto de ligação de domìnio bir da iap
|
|
WO2008014229A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
JP5452223B2
(ja)
*
|
2006-07-24 |
2014-03-26 |
テトラロジック ファーマシューティカルズ コーポレーション |
Ｉａｐ阻害剤
|
|
US20100143499A1
(en)
*
|
2006-07-24 |
2010-06-10 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
MX2009000824A
(es)
*
|
2006-07-24 |
2009-02-04 |
Tetralogic Pharmaceuticals Cor |
Antagonistas dimericos de las proteinas inhibidoras de la apoptosis.
|
|
WO2008014240A2
(en)
*
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
US20100056495A1
(en)
*
|
2006-07-24 |
2010-03-04 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
|
PE20110217A1
(es)
|
2006-08-02 |
2011-04-01 |
Novartis Ag |
DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
|
|
BRPI0719122A2
(pt)
*
|
2006-08-24 |
2013-12-10 |
Novartis Ag |
Compostos orgânicos
|
|
MX2009003080A
(es)
*
|
2006-09-22 |
2009-04-02 |
Novartis Ag |
Compuestos organicos heterociclicos.
|
|
AU2007307763A1
(en)
*
|
2006-10-12 |
2008-04-17 |
Novartis Ag |
Pyrrolydine derivatives as IAP inhibitors
|
|
CN101605786A
(zh)
*
|
2006-12-19 |
2009-12-16 |
健泰科生物技术公司 |
细胞凋亡抑制剂的咪唑并吡啶抑制剂
|
|
AU2007336238A1
(en)
*
|
2006-12-20 |
2008-06-26 |
Novartis Ag |
2-substituted 5-membered heterocycles as SCD inhibitors
|
|
CA2684169C
(en)
*
|
2007-04-12 |
2012-06-19 |
Joyant Pharmaceuticals, Inc. |
Smac mimetic dimers and trimers useful as anti-cancer agents
|
|
NZ598890A
(en)
*
|
2007-04-30 |
2013-10-25 |
Genentech Inc |
Inhibitors of iap
|
|
JP2010528587A
(ja)
*
|
2007-05-07 |
2010-08-26 |
テトラロジック ファーマシューティカルズ コーポレーション |
アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてＴＮＦα遺伝子の発現を用いる方法
|
|
WO2008144925A1
(en)
*
|
2007-05-30 |
2008-12-04 |
Aegera Therapeutics Inc. |
Iap bir domain binding compounds
|
|
DK2240506T3
(da)
*
|
2008-01-11 |
2013-04-08 |
Genentech Inc |
IAP inhibitorer
|
|
US20110117081A1
(en)
*
|
2008-05-05 |
2011-05-19 |
Aegera Therapeutics, Inc. |
Functionalized pyrrolidines and use thereof as iap inhibitors
|
|
US20110171171A1
(en)
*
|
2008-06-27 |
2011-07-14 |
Aegera Therapeutics, Inc. |
Bridged secondary amines and use thereof as iap bir domain binding compounds
|
|
US8835393B2
(en)
|
2008-08-02 |
2014-09-16 |
Genentech, Inc. |
Inhibitors of IAP
|
|
JP2012500272A
(ja)
*
|
2008-08-16 |
2012-01-05 |
ジェネンテック， インコーポレイテッド |
Ｉａｐのアザインドールインヒビター
|
|
AU2009293403A1
(en)
|
2008-09-17 |
2010-03-25 |
Tetralogic Pharmaceuticals Corp. |
IAP inhibitors
|
|
FR2939073B1
(fr)
|
2008-12-03 |
2010-12-31 |
Sidel Participations |
Formage des recipients avec contre-pression localisee
|
|
US20100317593A1
(en)
*
|
2009-06-12 |
2010-12-16 |
Astrazeneca Ab |
2,3-dihydro-1h-indene compounds
|
|
US8283372B2
(en)
*
|
2009-07-02 |
2012-10-09 |
Tetralogic Pharmaceuticals Corp. |
2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
|
|
JP2013505446A
(ja)
|
2009-09-18 |
2013-02-14 |
ノバルティス アーゲー |
Ｉａｐ阻害剤化合物のためのバイオマーカー
|
|
EP2493879B1
(en)
|
2009-10-28 |
2014-05-14 |
Joyant Pharmaceuticals, Inc. |
Dimeric smac mimetics
|
|
CN102050867A
(zh)
*
|
2009-11-10 |
2011-05-11 |
上海艾力斯医药科技有限公司 |
四肽类似物、制备方法及其应用
|
|
NZ602368A
(en)
*
|
2010-02-12 |
2014-10-31 |
Pharmascience Inc |
Iap bir domain binding compounds
|
|
CN103119034B
(zh)
|
2010-04-16 |
2016-08-03 |
拜耳知识产权有限责任公司 |
作为害虫防治剂的杂环化合物
|
|
GB201106817D0
(en)
|
2011-04-21 |
2011-06-01 |
Astex Therapeutics Ltd |
New compound
|
|
WO2013043591A1
(en)
*
|
2011-09-21 |
2013-03-28 |
Albert Einstein College Of Medicine Of Yeshiva University |
Combination therapy for cancer
|
|
JP2014528409A
(ja)
|
2011-09-30 |
2014-10-27 |
テトラロジック ファーマシューティカルズ コーポレーション |
増殖性疾患（がん）の治療において使用するためのＳＭＡＣ模倣体（ビリナパント（ｂｉｒｉｎａｐａｎｔ））
|
|
NO2755614T3
(enExample)
*
|
2012-01-03 |
2018-03-31 |
|
|
|
KR20150011822A
(ko)
|
2012-05-04 |
2015-02-02 |
노파르티스 아게 |
Iap 억제제 요법을 위한 바이오마커
|
|
CA2896577C
(en)
|
2012-11-30 |
2024-01-23 |
Sanford-Burnham Medical Research Institute |
Inhibitor of apoptosis protein (iap) antagonists
|
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
|
MX366978B
(es)
|
2013-03-15 |
2019-08-01 |
Novartis Ag |
Conjugados de anticuerpo - farmaco.
|
|
KR20160030099A
(ko)
|
2013-06-25 |
2016-03-16 |
더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 |
세포내 감염의 치료 방법
|
|
GB201311891D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compound
|
|
GB201311888D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
CN115368356B
(zh)
|
2013-12-20 |
2025-05-09 |
阿斯特克斯治疗有限公司 |
双环杂环化合物及其治疗用途
|
|
WO2015109391A1
(en)
|
2014-01-24 |
2015-07-30 |
Children's Hospital Of Eastern Ontario Research Institute Inc. |
Smc combination therapy for the treatment of cancer
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
WO2015168835A1
(en)
*
|
2014-05-05 |
2015-11-12 |
Empire Technology Development Llc |
Composite task processor
|
|
JP6768522B2
(ja)
|
2014-06-04 |
2020-10-14 |
サンフォード−バーンハム メディカル リサーチ インスティテュート |
Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用
|
|
WO2016020791A1
(en)
|
2014-08-05 |
2016-02-11 |
Novartis Ag |
Ckit antibody drug conjugates
|
|
MX2017001946A
(es)
|
2014-08-12 |
2017-06-19 |
Novartis Ag |
Conjugados de farmacos con anticuerpos anti-cdh6.
|
|
GB201414730D0
(en)
*
|
2014-08-19 |
2014-10-01 |
Tpp Global Dev Ltd |
Pharmaceutical compound
|
|
WO2016079527A1
(en)
|
2014-11-19 |
2016-05-26 |
Tetralogic Birinapant Uk Ltd |
Combination therapy
|
|
WO2016097773A1
(en)
|
2014-12-19 |
2016-06-23 |
Children's Cancer Institute |
Therapeutic iap antagonists for treating proliferative disorders
|
|
JP6817962B2
(ja)
|
2015-01-20 |
2021-01-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
ターゲティングされたアンドロゲン受容体分解のための化合物および方法
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
US20190194315A1
(en)
|
2015-06-17 |
2019-06-27 |
Novartis Ag |
Antibody drug conjugates
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
CR20180229A
(es)
|
2015-10-29 |
2018-08-24 |
Novartis Ag |
Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll
|
|
JP7164521B2
(ja)
|
2016-06-21 |
2022-11-01 |
オリオン・オフサルモロジー・エルエルシー |
炭素環式プロリンアミド誘導体
|
|
JP7179721B2
(ja)
|
2016-06-21 |
2022-11-29 |
オリオン・オフサルモロジー・エルエルシー |
複素環式プロリンアミド誘導体
|
|
MX2019005007A
(es)
|
2016-11-01 |
2019-07-18 |
Arvinas Inc |
Protac dirigidos a la proteína tau y métodos asociados de uso.
|
|
IL266842B
(en)
|
2016-12-01 |
2022-09-01 |
Arvinas Operations Inc |
History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
|
|
IL325835A
(en)
|
2016-12-23 |
2026-03-01 |
Univ Yale |
Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
|
|
CN110753693A
(zh)
|
2016-12-23 |
2020-02-04 |
阿尔维纳斯运营股份有限公司 |
Egfr蛋白水解靶向嵌合分子和相关使用方法
|
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
IL300417A
(en)
|
2017-01-26 |
2023-04-01 |
Arvinas Operations Inc |
Bifunctional benzothiophene compounds, preparations containing them and their use in therapy
|
|
JOP20190187A1
(ar)
|
2017-02-03 |
2019-08-01 |
Novartis Ag |
مترافقات عقار جسم مضاد لـ ccr7
|
|
WO2018163051A1
(en)
|
2017-03-06 |
2018-09-13 |
Novartis Ag |
Methods of treatment of cancer with reduced ubb expression
|
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
KR102920712B1
(ko)
|
2017-05-24 |
2026-01-30 |
노파르티스 아게 |
항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
|
|
US20200362058A1
(en)
|
2017-05-24 |
2020-11-19 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use
|
|
CN111247161B
(zh)
*
|
2017-11-13 |
2021-12-31 |
正大天晴药业集团股份有限公司 |
用作iap抑制剂的smac模拟物及其用途
|
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
|
JP7161849B2
(ja)
*
|
2018-01-24 |
2022-10-27 |
株式会社クラレ |
第一級アミンの製造方法
|
|
CN111655713B
(zh)
*
|
2018-02-09 |
2023-06-27 |
广东东阳光药业有限公司 |
Iap抑制剂及其在药物中的应用
|
|
BR112020020307A2
(pt)
|
2018-04-04 |
2021-01-12 |
Arvinas Operations, Inc. |
Moduladores de proteólise e métodos de uso associados
|
|
BR122022012697B1
(pt)
|
2018-07-10 |
2023-04-04 |
Novartis Ag |
Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
US20200038513A1
(en)
|
2018-07-26 |
2020-02-06 |
Arvinas Operations, Inc. |
Modulators of fak proteolysis and associated methods of use
|
|
US11707452B2
(en)
|
2018-08-20 |
2023-07-25 |
Arvinas Operations, Inc. |
Modulators of alpha-synuclein proteolysis and associated methods of use
|
|
CN119219628A
(zh)
|
2018-09-07 |
2024-12-31 |
阿尔维纳斯运营股份有限公司 |
用于迅速加速性纤维肉瘤多肽的靶向降解的多环化合物和方法
|
|
EP3873532A1
(en)
|
2018-10-31 |
2021-09-08 |
Novartis AG |
Dc-sign antibody drug conjugates
|
|
AU2019402189B2
(en)
|
2018-12-20 |
2023-04-13 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
AU2019409132B2
(en)
|
2018-12-21 |
2026-08-06 |
Novartis Ag |
Antibodies to PMEL17 and conjugates thereof
|
|
EP3924054B1
(en)
|
2019-02-15 |
2025-04-02 |
Novartis AG |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US20220175917A1
(en)
*
|
2019-03-07 |
2022-06-09 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Combination of iap inhibitor and immune checkpoint inhibitor
|
|
WO2020228642A1
(zh)
*
|
2019-05-10 |
2020-11-19 |
正大天晴药业集团股份有限公司 |
一种用作iap抑制剂的smac模拟物的结晶及其制备方法
|
|
EP3999182A1
(en)
|
2019-07-17 |
2022-05-25 |
Arvinas Operations, Inc. |
Tau-protein targeting compounds and associated methods of use
|
|
JP2022542437A
(ja)
|
2019-08-02 |
2022-10-03 |
ランティオペプ ベスローテン ヴェンノーツハップ |
癌の処置に用いるアンジオテンシン２型（ａｔ２）受容体アゴニスト
|
|
WO2021041348A1
(en)
|
2019-08-26 |
2021-03-04 |
Arvinas Operations, Inc. |
Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders
|
|
US12678509B2
(en)
|
2019-11-08 |
2026-07-14 |
Sanford Burnham Prebys Medical Discovery Institute |
Inhibitor of apoptosis (IAP) protein antagonists
|
|
US20230057071A1
(en)
|
2019-12-20 |
2023-02-23 |
Novartis Ag |
Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
|
|
US20230056604A1
(en)
|
2020-01-20 |
2023-02-23 |
Astrazeneca Ab |
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
|
|
CN111205232B
(zh)
*
|
2020-02-26 |
2022-07-01 |
浙江天宇药业股份有限公司 |
一种替格瑞洛中间体的合成方法
|
|
CN115210227A
(zh)
|
2020-03-04 |
2022-10-18 |
基因泰克公司 |
作为tead抑制剂的异双功能分子
|
|
US20230181756A1
(en)
|
2020-04-30 |
2023-06-15 |
Novartis Ag |
Ccr7 antibody drug conjugates for treating cancer
|
|
US20230332104A1
(en)
|
2020-06-11 |
2023-10-19 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
EP4168007A1
(en)
|
2020-06-23 |
2023-04-26 |
Novartis AG |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
WO2022047145A1
(en)
|
2020-08-28 |
2022-03-03 |
Arvinas Operations, Inc. |
Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
|
|
AU2021342287A1
(en)
|
2020-09-14 |
2023-04-13 |
Arvinas Operations, Inc. |
Crystalline forms of a compound for the targeted degradation of estrogen receptor
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
AU2022258829A1
(en)
|
2021-04-16 |
2023-10-26 |
Novartis Ag |
Antibody drug conjugates and methods for making thereof
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
JP2025524064A
(ja)
|
2022-07-26 |
2025-07-25 |
ノバルティス アーゲー |
Ａｋｒ１ｃ３依存性ｋａｒｓ阻害剤の結晶形態
|
|
EP4584258A1
(en)
|
2022-09-07 |
2025-07-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
|
PE20260006A1
(es)
|
2023-01-26 |
2026-01-06 |
Arvinas Operations Inc |
Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
|